Expecting First Results From Phase 1 Clinical Trials Of COVID-19 Vaccine In October
CureVac shares have been under selling pressure and fell ~20% in September. For the same period shares of key rivals Moderna and BioNTech rose 7%...
339 Views
CureVac May Supply ~225M of Potential COVID-19 Vaccine Doses. A Big Win Over Moderna and BioNTech
Today German coronavirus vaccine developer CureVac has concluded an Advanced Purchase Agreement (APA) to provide all EU Member States with up to...
334 Views
How High Can CureVac Stock Go After Blockbuster IPO? We Update Bull Case Scenario to $80 Per Share
CureVac stock closed at $55.90 per share during the first trading day, the best performance among biotech IPOs this year. Since the beginning of...
578 Views
CureVac IPO. Beating Rivals to Secure a COVID-19 Vaccine Based on MRNA Technology
German global clinical-stage biotech company and coronavirus vaccine developer CureVac set terms for $200M+ IPO (~13.3 million shares) at a...
518 Views